Skip to main content

JHOP - March 2018 Vol 8, No 1

Original Article

Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids

Kimberly N. Flynn, PharmD, BCPS, Celestine Gochett, PhD, AOCNS

Original Article

Microbial Growth of Single-Dose Antineoplastic Drug Vials at 28 Days

Elizabeth R. Pritchard, PharmD, BCOP, J. Aubrey Waddell, PharmD, FAPhA, BCOP, Brad J. Crane, PharmD, BCPS, Amy M. Porter, PharmD, Susan Roberts, PharmD, Danielle M. Yates, PharmD, Angelia M. Thomas, MT (ASCP)

FDA Updates

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, RPh, PhD

Case Reports

Aplastic Anemia in a Patient with Anaplastic Oligodendroglioma Postradiation and Concurrent Temozolomide Therapy: Case Report and Review of the Literature

Kirollos S. Hanna, PharmD, BCPS, BCOP, Robert Mancini, PharmD, BCOP, FHOPA, Matthew Burtelow, MD, PhD, Benjamin Bridges, MD

Symptom Management Overview

Prevention of Thromboembolism in Patients with Multiple Myeloma

Nicole Gerardo, PharmD

FDA Oncology Update

Recent Cancer Drugs Approved by the FDA

Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL

Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis

Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States

1
2

Page 1 of 2
Results 1 - 10 of 15